No Histological Difference between Large Atherosclerotic and Cardiogenic Embolic Thrombus.
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
12
2021
revised:
17
01
2022
accepted:
26
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
25
3
2022
Statut:
epublish
Résumé
The continuous development of endovascular treatment technology provides more opportunities for the histological study of thrombus. According to Trial of Org 10 172 in Acute Stroke Treatment (TOAST), clinicians take different strategies in anticoagulant or antiplatelet therapy. There are some patients still suffering from recurrent stroke while they took anticoagulant or antiplatelet drugs regularly for secondary prevention. In view of that, we found that histological analysis of thrombus can provide guidance for secondary prevention. Exploring the histological characteristics differences between large atherosclerotic and cardiogenic embolic thrombosis in order to guide clinical secondary prevention of the two stroke subtypes. A total of 54 patients with acute ischemic stroke were collected from December 2019 to April 2021. Identify stroke subtypes according to TOAST classification. Stain thrombus specimens with hematoxylin-eosin staining, and perform statistical analysis on the components (red blood cells and fibrin/platelets) of thrombus. In cardiogenic thrombi, the composition of RBCs was dominant (51.38 ± 18.463%) compared to that of fibrin/platelets (48.62 ± 18.463%). Similarly, among the thrombi of large artery atherosclerotic, RBCs (50.40 ± 20.100%) compared to fibrin/platelets (49.60 ± 20.100%). There was no statistical difference in RBCs or fibrin/platelet composition of both cardiogenic and atherosclerotic thrombi ( The histologic composition of thrombi in cardiogenic and atherosclerotic had no statistical difference. These thrombi are all mixed thrombus, which are rich in RBCs, fibrinogen, and platelets. Anticoagulation combined with antiplatelet may be a more effective secondary prevention strategy.
Sections du résumé
Background
UNASSIGNED
The continuous development of endovascular treatment technology provides more opportunities for the histological study of thrombus. According to Trial of Org 10 172 in Acute Stroke Treatment (TOAST), clinicians take different strategies in anticoagulant or antiplatelet therapy. There are some patients still suffering from recurrent stroke while they took anticoagulant or antiplatelet drugs regularly for secondary prevention. In view of that, we found that histological analysis of thrombus can provide guidance for secondary prevention.
Aim
UNASSIGNED
Exploring the histological characteristics differences between large atherosclerotic and cardiogenic embolic thrombosis in order to guide clinical secondary prevention of the two stroke subtypes.
Methods
UNASSIGNED
A total of 54 patients with acute ischemic stroke were collected from December 2019 to April 2021. Identify stroke subtypes according to TOAST classification. Stain thrombus specimens with hematoxylin-eosin staining, and perform statistical analysis on the components (red blood cells and fibrin/platelets) of thrombus.
Results
UNASSIGNED
In cardiogenic thrombi, the composition of RBCs was dominant (51.38 ± 18.463%) compared to that of fibrin/platelets (48.62 ± 18.463%). Similarly, among the thrombi of large artery atherosclerotic, RBCs (50.40 ± 20.100%) compared to fibrin/platelets (49.60 ± 20.100%). There was no statistical difference in RBCs or fibrin/platelet composition of both cardiogenic and atherosclerotic thrombi (
Conclusions
UNASSIGNED
The histologic composition of thrombi in cardiogenic and atherosclerotic had no statistical difference. These thrombi are all mixed thrombus, which are rich in RBCs, fibrinogen, and platelets. Anticoagulation combined with antiplatelet may be a more effective secondary prevention strategy.
Identifiants
pubmed: 35281464
doi: 10.1155/2022/4845264
pmc: PMC8916853
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4845264Informations de copyright
Copyright © 2022 Rui Chen et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Stroke. 2013 Jan;44(1):243-5
pubmed: 23111438
Cochrane Database Syst Rev. 2015 Mar 12;(3):CD000024
pubmed: 25764172
Stroke. 2006 Aug;37(8):2086-93
pubmed: 16794209
J Thromb Haemost. 2014 Jun;12(6):987-98
pubmed: 24655807
Vasc Health Risk Manag. 2015 Aug 07;11:437-50
pubmed: 26300647
Stroke. 2011 May;42(5):1237-43
pubmed: 21393591
Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):271-279
pubmed: 27908894
Stroke. 2013 Oct;44(10):2955-6
pubmed: 24046010
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Stroke. 1996 May;27(5):875-81
pubmed: 8623107
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Stroke. 2015 Mar;46(3):746-56
pubmed: 25613308
Int J Stroke. 2016 Dec;11(9):1036-1044
pubmed: 27056965
Rev Esp Cardiol. 2009 Sep;62(9):992-1000
pubmed: 19712620
Haematologica. 2020 Jan 31;105(2):498-507
pubmed: 31048352
Health Technol Assess. 2013 Jul;17(30):1-188
pubmed: 23880057
Clin Neuroradiol. 2016 Jun;26(2):189-97
pubmed: 25261075
N Engl J Med. 1995 Dec 14;333(24):1581-7
pubmed: 7477192
J Neurointerv Surg. 2021 Aug;13(8):738-740
pubmed: 33115814
Curr Pharm Des. 2018;24(38):4511-4515
pubmed: 30585539
Stroke. 2007 Feb;38(2):423-30
pubmed: 17204681
Lancet Neurol. 2014 Feb;13(2):178-94
pubmed: 24361114
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Circulation. 2019 Apr 30;139(18):2170-2185
pubmed: 31034291